S-100β and MIA in advanced melanoma in relation to prognostic factors

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1779-1782

  Auge, J M ^a   Molina, R ^a   Filella, X ^a   Bosch, E ^a   Gonzalez Cao, M ^a   Puig, S ^a   Malvehy, J ^a   Castel, T ^a   Ballesta, A M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Malignant melanoma; MIA; Prognostic factors; S 100; Tumor marker

Indexed keywords

MELANOMA INHIBITING ACTIVITY; PROTEIN S100B; TUMOR MARKER; UNCLASSIFIED DRUG; MIA ANTIGEN, HUMAN; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; ARTICLE; BLOOD; CASE CONTROL STUDY; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CASE-CONTROL STUDIES; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; PROGNOSIS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 21244439508     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Brochez L and Naeyaert JM: Understanding the trends in melanoma incidence and mortality: where do we stand? Eur J Dermatol 10: 71-75, 2000.
2. Dennis LK: Analysis of the melanoma epidemic, both apparent and real: data from the 1973 throug 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 135: 275-80, 1999.
3. Fagnart OC, Sindic CJM and Laterre C: Particle counting immunoassay of S100 protein in serum: Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34: 1387-1391, 1988.
4. Deichmann M, Brenner A, Bock M, Jäckel A, Uhl K, Waldmann V et al: S100-beta, melanoma inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17: 1891-6, 1999.
5. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D et al: Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3: 558-63, 1996.
6. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E et al: Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9: 155-61, 1999.
7. von Schoultz E, Hansson LO, Djureen E, Hansson J, Karnell R, Nilsson B et al: Prognostic value of serum analyses of S-100b protein in malignant melanoma. Melanoma Res 6: 133-7, 1996.
8. Bonfrer JMG, Korse CM and Israels SP: Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res 17: 2975-8, 1997.
9. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R et al: Melanomainhibiting activity: A novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149-3153, 1997.
10. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R and Bosserhoff A: Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol 22: 54-8, 2001.
11. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G et al: Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97: 1737-45, 2003.
12. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A et al: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54: 5695-5701, 1994.
13. Bosserhoff AK, Golob M, Buettner R, Landthaler M and Hein R: MIA (melanoma inhibitory activity). Biological functions and clinical relevance. Hautarzt 49: 762-9, 1998.
14. Dietz UH and Sandell LJ: Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem 277: 3311-6, 1996.
15. Bosserhoff AK, Kondo S, Moser M, Dietz UH, Copeland NG, Gilbert DJ et al: Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn 208: 516-525, 1997.
16. Muller-Ladner U, Bosserhoff AK, Dreher K, Mein R, Neidhart M, Gay S et at: MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology 38: 148-54, 1999.
17. Matsuhita Y, Hatta N, Wakamatsu K, Takehara K, Ito S and Takata M: Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-s-cysteinyldopa. Melanoma Res 12: 319-23, 2002.
18. Faries MB, Gupta RK, Ye X, Hsueh EC and Morton DL: Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III Melanoma. Ann Surg Oncol 11: 85-93, 2004.
19. Schmitz C, Brenner W, Henze E, Christophers E and Hauschild A: Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 20: 5059-63, 2000.
20. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al: Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-48, 2001.
21. Molina R, Navarro J, Filella X, Castel T and Ballesta AM: S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23: 39-44, 2002.
22. Berking C, Schlupen EM, Schrader A, Atzpodien J and Volkenandt M: Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res 291: 479-84, 1999.
23. Schultz ES, Diepgen TL and von den Driesch P: Clinical and prognostic relevance of serum S-100b protein in malignant melanoma. Br J Dermatol 138: 426-30, 1998.
24. Abraha HD, Butterworth RJ, Bath PMW, Wassif WS, Garthwaite J and Sherwood RA: Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 34: 366-370, 1997.
25. Kapural M, Krizanac-Bengez Lj, Barnett G, Perl J, Masaryk T, Apollo D et al: Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res 940: 102-4, 2002.
26. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH and Lamers KJ: Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-IOOB and glial fibrillary acidic protein. Stroke 31: 2670-7, 2000.
27. European Group on Tumor Markers: European Group on Tumor Markers: Consensus recommendations. Anticancer Res 19: 2785-2820, 1999.
28. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E et al: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56: 338-44, 1999.
29. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Br Cancer Res Treat 36: 41-48, 1995.
30. Richard MA, Grob JJ, Avril MF, Delaunay M, Thirion X, Wolkenstein P et al: Melanoma and tumor thickness. Arch Dermatol 135: 268-274, 1999.